Boston Scientific Announces Completion of Tender Offer for Rubicon Medical Corporation

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
RM Secured C	LSE:RMDC	London	Ordinary Share	GB00BFX12M00	C SHS 10P

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

RM Secured C

LSE:RMDC

London

Ordinary Share

GB00BFX12M00

C SHS 10P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	101.00	100.00	102.00				0.00	01:00:00

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

101.00

100.00

102.00

0.00

01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

N/A

Boston Scientific Announces Completion of Tender Offer for Rubicon Medical Corporation

02/06/2005 11:00pm

PR Newswire (US)

RM Secured C (LSE:RMDC)
Historical Stock Chart

From Jul 2019 to Jul 2024

Click Here for more RM Secured C Charts.

Boston Scientific Announces Completion of Tender Offer for Rubicon Medical Corporation NATICK, Mass., June 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) today announced the completion of the cash tender offer for any and all outstanding shares of common stock of Rubicon Medical Corporation (OTC:RMDC) (BULLETIN BOARD: RMDC) . The tender offer, which commenced on May 3, 2005, expired at 12:00 midnight (ET), on Wednesday, June 1, 2005. Based on preliminary information provided by The Bank of New York, the depositary for the offer, 30,832,649 shares of Rubicon's common stock were tendered into the offer, which, when combined with the Rubicon stock already owned by Boston Scientific, represents approximately 96 percent of Rubicon's outstanding common stock on a fully diluted basis. Nemo I Acquisition, Inc., the wholly-owned subsidiary of Boston Scientific through which the tender offer was made, has accepted for payment all validly tendered shares and will make prompt payment for the accepted shares. Boston Scientific intends to acquire the remaining shares of Rubicon common stock in a merger in which all remaining Rubicon stockholders who did not tender their shares in the tender offer will receive the same consideration as those who tendered, namely $1.50 per share in cash, without interest, together with the right to receive additional payments in the aggregate amount of up to $1.44 per share in cash, without interest, if certain milestones are achieved relating to Rubicon's embolic protection filter device and similar products. Because Boston Scientific has acquired more than 90 percent of the outstanding Rubicon shares, a stockholder vote is not required to approve the merger. Boston Scientific intends to complete the merger in the next several days. Boston Scientific will promptly mail to stockholders who did not tender their shares relevant information on how to receive payment. About Boston Scientific Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/. About Rubicon Medical Rubicon Medical Corporation (http://www.rubiconmed.com/) is a Salt Lake City-based developer and manufacturer of interventional vascular medical devices and products. CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation DATASOURCE: Boston Scientific CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Paul Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific Corporation Web site: http://www.bostonscientific.com/ http://www.rubiconmed.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

RMDC RM Secured C